Concepedia

Katherine A. Minson

KA

Statistics

Publications

6

Citations

329

H-Index

6

Active since

2014

Affiliations

University of North Carolina at Chapel Hill(Current)

Children's Healthcare of Atlanta

Emory University

University of Colorado Denver

Aflac (United States)

Katherine A. Minson is an author at University of North Carolina at Chapel Hill specializing in medicine, pharmacology, and pharmacotherapy.

Top concepts

MedicinePharmacologyCell BiologyDrug DiscoveryCancer ResearchPharmacotherapyOncologyTumor BiologySystems BiologyDrug Development

Publications per year

2014–2021

6

Publications

6

<b>UNC2025</b>, a Potent and Orally Bioavailable MER/FLT3 Dual Inhibitor

Weihe Zhang, Deborah DeRyckere, Debra M. Hunter et al. · Journal of Medicinal Chemistry · 2014 · 157 citations · Full text

Useful Selectivity, Pharmacotherapy, Pharmaceutical Chemistry +18

The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia

Katherine A. Minson, Catherine C. Smith, Deborah DeRyckere et al. · JCI Insight · 2016 · 75 citations · Full text

Fms-like Tyrosine Kinase, Mixed-phenotype Acute Leukemia, Resistance-conferring Flt3 Mutations +17

Inhibition of MERTK Promotes Suppression of Tumor Growth in BRAF Mutant and BRAF Wild-Type Melanoma

Lenka Sinik, Katherine A. Minson, John J. Tentler et al. · Molecular Cancer Therapeutics · 2018 · 31 citations · Full text

The small‐molecule MERTK inhibitor UNC2025 decreases platelet activation and prevents thrombosis

Brian R. Branchford, Timothy J. Stalker, Luke Law et al. · Journal of Thrombosis and Haemostasis · 2017 · 30 citations · Full text

Platelet Biology, Molecular Pharmacology, Thrombosis +12

Data-Driven Construction of Antitumor Agents with Controlled Polypharmacology

Chenxiao Da, Dehui� Zhang, Michael A. Stashko et al. · Journal of the American Chemical Society · 2019 · 20 citations · Full text

Drug Target, Large Protein Family, Tumor Biology +16

1–5 of 6